More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes

On 9 December2019, the Institute for Clinical and Economic Review (ICER) released its final evidence report to establish the value of oral semaglutide (Novo Nordisk) for Type 2 diabetes (T2DM). A key element in this report was the development of a lifetime cost effectiveness microsimulation model ba...

Descripción completa

Detalles Bibliográficos
Autor principal: Langley, Paul C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of Minnesota Libraries Publishing 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132533/
https://www.ncbi.nlm.nih.gov/pubmed/34017637
http://dx.doi.org/10.24926/iip.v11i1.2420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132533/
https://www.ncbi.nlm.nih.gov/pubmed/34017637
http://dx.doi.org/10.24926/iip.v11i1.2420

Ejemplares similares